DK2176664T3 - Ccr4 som cancermarkør - Google Patents

Ccr4 som cancermarkør

Info

Publication number
DK2176664T3
DK2176664T3 DK08806315.1T DK08806315T DK2176664T3 DK 2176664 T3 DK2176664 T3 DK 2176664T3 DK 08806315 T DK08806315 T DK 08806315T DK 2176664 T3 DK2176664 T3 DK 2176664T3
Authority
DK
Denmark
Prior art keywords
ccr4
cancer marker
marker
cancer
Prior art date
Application number
DK08806315.1T
Other languages
Danish (da)
English (en)
Inventor
Frances Balkwill
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2176664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK2176664T3 publication Critical patent/DK2176664T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08806315.1T 2007-09-18 2008-09-18 Ccr4 som cancermarkør DK2176664T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Publications (1)

Publication Number Publication Date
DK2176664T3 true DK2176664T3 (da) 2014-01-20

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Country Status (11)

Country Link
US (2) US9134293B2 (cg-RX-API-DMAC7.html)
EP (3) EP2176664B1 (cg-RX-API-DMAC7.html)
JP (2) JP5774309B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008300413B2 (cg-RX-API-DMAC7.html)
CA (1) CA2699702C (cg-RX-API-DMAC7.html)
DK (3) DK2176664T3 (cg-RX-API-DMAC7.html)
ES (3) ES2612690T3 (cg-RX-API-DMAC7.html)
GB (1) GB0718167D0 (cg-RX-API-DMAC7.html)
PL (3) PL2535716T3 (cg-RX-API-DMAC7.html)
RU (2) RU2529797C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009037454A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
US9229004B2 (en) 2008-09-26 2016-01-05 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
EP2771488B1 (en) 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
KR102000770B1 (ko) 2011-12-01 2019-07-16 케모센트릭스, 인크. Ｃｃｒ(4) 길항제로서의 치환된 아닐린
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
EA034655B1 (ru) * 2013-11-06 2020-03-03 Янссен Байотек, Инк. Антитела к ccl17
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA2962812A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
BR112017022320A2 (pt) * 2015-04-17 2018-07-24 Morphotek Inc métodos para tratamento de câncer de pulmão
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
US20210163607A1 (en) * 2017-05-19 2021-06-03 Nippon Zenyaku Kogyo Co., Ltd. Method for suppressing regulatory t cell infiltration by ccr4 inhibition and method for treating canine neoplastic disease
WO2020047030A1 (en) 2018-08-29 2020-03-05 Chemocentryx, Inc. Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
US20020132836A1 (en) 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
WO2002030358A2 (en) 2000-10-11 2002-04-18 Tularik Inc. Modulation of ccr4 function
SK4702003A3 (en) 2000-10-18 2004-01-08 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
AU2002254076A1 (en) * 2001-02-28 2002-09-12 Protein Desing Labs, Inc. Chemokine receptors and disease
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
WO2003014153A2 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use.
ATE490277T1 (de) 2001-08-31 2010-12-15 Kyowa Hakko Kirin Co Ltd Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP1592708A2 (en) * 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
CA2542037A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition of antibody capable of specifically binding ccr4
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ES2397803T3 (es) 2006-02-14 2013-03-11 Noxxon Pharma Ag Ácidos nucleicos de unión a MCP-1
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
ES2588507T3 (es) 2016-11-03
JP2010539508A (ja) 2010-12-16
CA2699702C (en) 2018-03-06
DK2535716T3 (en) 2017-02-13
DK2533047T3 (en) 2016-08-22
ES2612690T3 (es) 2017-05-18
WO2009037454A2 (en) 2009-03-26
PL2176664T3 (pl) 2014-04-30
RU2010123921A (ru) 2011-12-20
US9134293B2 (en) 2015-09-15
RU2014128513A (ru) 2016-02-10
PL2533047T3 (pl) 2016-11-30
AU2008300413B2 (en) 2014-09-11
EP2176664B1 (en) 2013-11-06
US20100278844A1 (en) 2010-11-04
RU2529797C2 (ru) 2014-09-27
US10261099B2 (en) 2019-04-16
ES2443541T3 (es) 2014-02-19
EP2535716B1 (en) 2016-11-02
AU2008300413A1 (en) 2009-03-26
EP2176664A2 (en) 2010-04-21
EP2535716A2 (en) 2012-12-19
US20160223572A1 (en) 2016-08-04
GB0718167D0 (en) 2007-10-31
EP2535716A3 (en) 2013-03-13
EP2533047A1 (en) 2012-12-12
WO2009037454A3 (en) 2009-05-07
JP2015212703A (ja) 2015-11-26
EP2533047B1 (en) 2016-05-11
JP5774309B2 (ja) 2015-09-09
JP6234967B2 (ja) 2017-11-22
CA2699702A1 (en) 2009-03-26
PL2535716T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
DK2176664T3 (da) Ccr4 som cancermarkør
EP2115162A4 (en) Adrb2 cancer markers
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0813500A2 (pt) Compostos antivirais
ATE518837T1 (de) Indazolamidderivate
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0811264A2 (pt) Compostos
DK2152885T3 (da) Polynukleotidmarkører
EP2216388A4 (en) STRUCTURE OF GLISSOIR
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
ATE519760T1 (de) Isoxazolimidazolderivate
DE602008001646D1 (de) Sprühvorrichtung
BRPI0815181A2 (pt) Compostos
ATE546446T1 (de) 5-aminocyclylmethyl-oxazolidin-2-eins-derivativ
NO20071562L (no) Beleggingssammensetning
EP2202090A4 (en) MECHANICAL PIN
CR9342S (es) Regadera
DE502006006067D1 (de) Ng
BRPI0818645A2 (pt) Lápis
ATE467626T1 (de) Indol-2-yl-piperazin-1-yl-methanon-derivate
BRPI0814613A2 (pt) Compostos